JAK1 and congenital rubella syndrome: However, robust upregulation of STAT1 in the intestines and significant protection conferred by the JAK-1/2 inhibitor, ruxolitinib suggested that IFN-γ -JAK-1/2- STAT1 pathway may play a major role in inducing small intestinal immunopathology in SAg-induced CRS.